# Poolbeg Pharma Positive Conclusion Reached in Immunomodulator I Patent Opposition

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-positive-conclusion-reached-in-immunomodulator-i-patent-opposition/4121128561
- Published: 2023-09-29T07:32:21+01:00
- Author: Ethan Davis

**Poolbeg Pharma** ([LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF), a clinical-stage biopharmaceutical company targeting diseases with
a high unmet medical need, announces that further to its announcement on 19 September
2023, the oral opposition hearing scheduled by the European Patent Office (‘EPO’)
relating to the challenge to the Company’s European patent (Immunomodulator I), 
has been cancelled. This favourably concludes this matter with the patent maintained
as granted.

The Immunomodulator I European patent was opposed by a third party in September 
2021 and the opposition was subsequently withdrawn in September 2023. Following 
the opposition withdrawal, the EPO has now concluded that there is no need to proceed
with the scheduled hearing, concluding this matter.

> **Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:** _“
> I am delighted to share that the European Patent Office has decided against proceeding
> with the scheduled hearing, following the withdrawal of the patent opposition 
> by a third party. We have always maintained confidence in the strength and validity
> of our patents and we are pleased to bring this matter to a close and look forward
> to continuing to strengthen our IP protection of this exciting molecule.”_

Footnote:

Immunomodulator I: Use of p38 MAPK inhibitors for the treatment of severe influenza

Poolbeg Pharma specialises in the development of innovative medicines to address
the unmet need in infectious and other prevalent diseases. Poolbeg Pharma has a 
disciplined portfolio approach to mitigate risk, accelerate drug development, and
enhance investor returns. The Company simultaneously advances multiple programmes
in cost-effective clinical trials, rapidly generating early human safety and efficacy
data to enable early partnering / out-licensing, with the funds generated reinvested
in the pipeline. Poolbeg Pharma also uses AI to interrogate human challenge trial
data sets to quickly identify new targets and drugs, leading to faster development
and greater commercial appeal.

The Company is targeting the growing infectious disease market. In the wake of the
COVID-19 pandemic, infectious disease has become one of the fastest growing pharma
markets and is expected to exceed $250bn by 2025. Through opportunistic identification
of assets which complement Poolbeg Pharma’s existing pipeline, the Company is progressing
programmes in oncology and metabolic syndromes; adding disease areas with significant
addressable markets.

Share on:
